Results 181 to 190 of about 280,656 (362)

Dynamics of Apolipoprotein J Levels and Metabolic Parameters Following Bariatric Surgery

Clinical Endocrinology, EarlyView.
ABSTRACT Objective Bariatric surgery has emerged as a potent intervention for ameliorating insulin resistance and its associated comorbidities in obese patients. Apolipoprotein J (ApoJ) and adiponectin are closely associated with insulin resistance and sensitivity, respectively.
Kellen Cristina da Cruz Rodrigues, Minjin Lee, Yejee Lim, Jennie Young, Brendon Chung, Susan Phillips, Theodore P. Ciaraldi, Young‐Bum Kim   +7 more
wiley   +1 more source

Coronary artery bypass grafting after pneumonectomy [PDF]

, 2001
Khalil Diab
openalex   +1 more source

Age disparities in SGLT2 inhibitor prescription among people with type 2 diabetes: The role of frailty and sex

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Background Older adults with type 2 diabetes (T2DM) are less likely to receive sodium–glucose cotransporter‐2 (SGLT2) inhibitors, despite their proven cardio‐renal benefits and safety. Whether this age‐related gap is driven by frailty, sex, or other factors remains unclear.
Changyuan Yang, Petra Denig, Lynne Chepulis, Ryan G. Paul, Jung‐Im Shin, Ron T. Gansevoort, Priya Vart   +6 more
wiley   +1 more source

Subclinical Hypothyroidism as a Risk for Coronary Artery Bypass Grafting. [PDF]

Cardiovasc Ther
Martins RM, Pittella FJM, de Oliveira BC, Lima BGS, Ferreira CC, Pereira AD, Martins WA, Filho RAC, Lima GAB.   +8 more
europepmc   +1 more source

Coagulation, fibrinolysis, and cell activation in patients and in shed mediastinal blood during coronary artery bypass grafting with a new heparin-coated surface [PDF]

, 2003
Christophe Baufreton, Jean Louis de Brux
openalex   +1 more source

Semaglutide and tirzepatide effects on cardiovascular outcomes in people with overweight or obesity in the real world (STEER)

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims To assess the real‐world effectiveness of semaglutide versus tirzepatide in reducing major adverse cardiovascular events (MACE) among patients with overweight/obesity and established atherosclerotic cardiovascular disease (ASCVD) without diabetes in an insured US population.
Lauren Wilson, Zhenxiang Zhao, Victoria Divino, Matthew Bassan, Bríain Ó. Hartaigh, Signe Stensen, Kerem Ozer   +6 more
wiley   +1 more source

Coronary artery bypass grafting in patients with hematological neoplasms. [PDF]

Front Cardiovasc Med
Zhang L, Zhang S, Jiang H, Liu J, Gao Q, Lian B, Liu Z, Shi Y.   +7 more
europepmc   +1 more source

Results of Off-Pump Coronary Artery Bypass Surgery in Patients with EuroSCORE≥5

, 2019
Islamjan Sharipov, Shavkat Karimov, R. D. Kurbanov   +2 more
openalex   +1 more source

Effect of empagliflozin on urinary albumin excretion and hypoxic biomarkers in early diabetic kidney disease: A randomised double‐blind, placebo‐controlled trial

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims The precise mechanism of sodium glucose co‐transporter 2 (SGLT2) inhibitor on reno‐protective effect has been still unclear. In this study, we hypothesised that SGLT2 inhibitor prevents diabetic kidney disease via reduction of hypoxia‐induced factors.
Hisashi Makino, Masato Kasahara, Ryuzo Takashima, Shu Kasama, Naoki Ozu, Hyohun Park, Qingxing Chen, Kazuhiko Tsuruya, Mayu Tochiya, Yoko Omura‐Ohata, Tamiko Tamanaha, Michio Noguchi, Takeshi Aiba, Fumiki Yoshihara, Kiminori Hosoda   +14 more
wiley   +1 more source

Etiology of Coronary Reintervention After Coronary Artery Bypass Surgery. [PDF]

J Cardiovasc Dev Dis
Achbar I, Görtzen QFN, Ter Woorst JFJ, Teeuwen K, Tonino PAL, Akca F.   +5 more
europepmc   +1 more source